Main Article Content
Purpose: To study the effectiveness of formoterol fumarate tablets when used in combination with interventional bronchoscopy for central airway tumor.
Methods: A total of 154 central airway tumor patients on admission in Second Affiliated Hospital of Zunyi Medical University, Zunyi, China (August 2020 - December 2022) were assigned to benign group (BG, n = 70) and malignant group (MG, n = 84), based on the nature of tumor lesion. The patients were administered formoterol fumarate tablets as well as interventional bronchoscopy. Clinical efficacy, lung function indices such as forced expiratory volume in one second (FEV1), forced vital capacity (FVC) and FEV1/FVC ratio, blood gas indices (pH, partial pressure of oxygen (PaO2) and partial pressure of carbon dioxide (PaCO2)), scores on shortness of breath, and survival rate, were determined and compared between the two groups.
Results: The overall effectiveness in BG (97.14 %) was significantly higher than that in MG (84.52 %). There were higher post-treatment values of FEV1, FVC and FEV1/FVC; higher values of pH and PaO2, lower PaCO2, and lower scores on shortness of breath in BG and MG, relative to pre- treatment levels (p < 0.05). Follow-up showed no recurrence in patients with benign tumor, and clinical efficacy was satisfactory. The 2-year survival rate of patients with malignant tumor was 51.19 %.
Conclusion: The combination of formoterol fumarate tablets and interventional bronchoscopy produces significant curative effect on benign and malignant tumor in central airway. It improves lung function, blood gas indices and survival rate, and mitigates shortness of breath. Therefore, this treatment strategy has a high potential for use in clinical practice.